MET and renal carcinoma: Renal cancer cells are dependent on Receptor Tyrosine Kinases (RTK) like c-MET for their survival and RTK targeted therapeutics (like, sorafenib, sunitinib, cabozantinib and others) are being used in the first-line of treatment of RCC [2–4].